Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

A novel crosstalk mechanism between nuclear receptor-mediated and growth factor/Ras-mediated pathways through PNRC–Grb2 interaction

Abstract

It has been demonstrated that proline-rich nuclear receptor coregulatory protein (PNRC) is a nuclear receptor coactivator that interacts with nuclear receptors through an SH3-binding motif located in its C-terminus. In the present report, a physical interaction between PNRC and Grb2 (an adapter protein involved in growth factor/Ras-mediated pathways) has been demonstrated using the GST pull-down assay, the yeast two-hybrid assay, as well as by coimmunoprecipitation. Cotransfection and fluorescence imaging have also confirmed the colocalization of PNRC and Grb2 in mammalian cells. Transient transfection experiments have demonstrated that, by interacting with each other, Grb2 decreases the coactivator activity of PNRC for nuclear receptors, and that PNRC suppresses Grb2-mediated Ras/MAP-kinase activation. Furthermore, it was discovered that HeLa cells overexpressing PNRC grew more slowly when compared to matched controls. Additionally, using a RT–PCR analysis of mRNA on six pairs of cancer/noncancer tissues, PNRC expression was found to be significantly lower in breast cancer tissue than in noncancer tissue. Based on these findings, we believe that PNRC and Grb2, by interacting with each other, can suppress nuclear receptor-mediated regulation and growth factor-mediated regulation in human breast tissue. This is a newly identified crosstalk mechanism for modulating these two important types of regulatory pathways.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 6
Figure 7
Figure 4
Figure 5

Similar content being viewed by others

References

  • Chen S, Zhou D, Yang C and Sherman M . (2001). J. Biol. Chem., 276, 28465–28470.

  • Cheng AM, Saxton TM, Sakai R, Kulkarni S, Mbamalu G, Vogel W, Tortorice CG, Cardiff RD, Cross JC, Muller WJ and Pawson T . (1998). Cell, 95, 793–803.

  • Cussac D, Vidal M, Leprince C, Liu WQ, Cornille F, Tiraboschi G, Roques BP and Garbay C . (1999). FASEB J., 13, 31–38.

  • DeMore JF and Brown M . (2000). Mol. Cell. Biol., 20, 5041–5047.

  • Gay B, Suarez S, Caravatti G, Furet P, Meyer T and Schoepfer J . (1999). Int. J. Cancer, 83, 235–241.

  • Glass CK, Rose DW and Rosenfeld MG . (1997). Curr. Opin. Cell Biol., 9, 222–232.

  • Harris RA, Eichholtz TJ, Hiles ID, Page MJ and O'Hare MJ . (1999). Int. J. Cancer, 80, 477–484.

  • Heery DM, Kalkhoven E, Hoare S and Parker MG . (1997). Nature, 387, 733–736.

  • Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS and Tung L . (1996). Mol. Endocrinol., 10, 1167–1177.

  • Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E and Kawashima H . (1995). Science, 270, 1491–1494.

  • Lowenstein EJ, Daly RJ, Batzer AG, Li W, Margolis B, Lammers R, Ullrich A, Skolnik EY, Bar-Sagi D and Schlessinger J . (1992). Cell, 70, 431–442.

  • Nelson RM and Long GL . (1989). Anal. Biochem., 180, 147–151.

  • Nicholson RI and Gee JWM . (1996). Hormone and Cancer, Vedeckis WV (ed). Birkhauser: Boston, pp 227–261.

    Google Scholar 

  • Ordentlich P, Downes M and Evans RM . (2001). Curr. Top. Microbiol. Immunol., 254, 101–116.

  • Pawson T . (1995). Nature, 373, 573–580.

  • Rauh MJ, Blackmore V, Andrechek ER, Tortorice CG, Daly R, Lai VK, Pawson T, Cardiff RD, Siegel PM and Muller WJ . (1999). Mol. Cell. Biol., 19, 8169–8179.

  • Rooij JD and Bos JL . (1997). Oncogene, 14, 623–625.

  • Russell KS and Hung MC . (1992). Cancer Res., 52, 6624–6629.

  • Tari AM, Hung MC, Li K and Lopez-Berestein G . (1999). Oncogene, 19, 1325–1332.

  • Verbeek BS, Adriaansen-Slot SS, Rijksen G and Vroom TM . (1997). J. Pathol., 183, 195–203.

  • Zhou D and Chen S . (2001). Nucleic Acids Res., 29, 3939–3948.

  • Zhou D, Quach KM, Yang C, Lee SY, Pohajdak B and Chen S . (2000). Mol. Endocrinol., 14, 986–998.

Download references

Acknowledgements

We are grateful to Dr Peter S McPherson, Montreal Neurological Institute, McGill University for pGEX2T-Raf/RBD expression plasmid. This research was supported by NIH Grants DK60560 and CA44735. Bin Chen was supported by Chinese National Nature Foundation Grant 30300126.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Shiuan Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhou, D., Chen, B., Ye, JJ. et al. A novel crosstalk mechanism between nuclear receptor-mediated and growth factor/Ras-mediated pathways through PNRC–Grb2 interaction. Oncogene 23, 5394–5404 (2004). https://doi.org/10.1038/sj.onc.1207695

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207695

Keywords

This article is cited by

Search

Quick links